Table 2.

The clinical symptoms of participants at baseline

Characteristics	Revision surgery (N = 22)	Omalizumab (N = 22)	P value
SNOT-22 (scale 0–110), median (IQR)	38.75 (38.75–79.00)	47.00 (26.00–64.50)	0.1386
Rhinologic symptoms (scale 0–30), median (IQR)	19.50 (16.00–23.25)	16.50 (10.75–22.50)	0.2128
Extranasal rhinologic symptoms (scale 0–15), median (IQR)	13.00 (10.00–14.00)	11.00 (5.75–13.50)	0.1555
Ear/facial symptoms (scale 0–25), median (IQR)	10.50 (4.50–12.25)	7.00 (2.00–11.25)	0.1755
Psychological dysfunction (scale 0–35), median (IQR)	15.00 (7.00–28.75)	11.00 (5.50–20.25)	0.3600
Sleep dysfunction (scale 0–25), median (IQR)	10.50 (7.75–21.25)	8.00 (4.00–12.50)	0.0670
Visual analog scale, VAS (scale 0–10)
Nasal obstruction, median (IQR)	8.50 (7.00–9.50)	7.00 (6.48–8.48)	0.0257∗
Runny nose, median (IQR)	7.75 (4.75–9.00)	6.35 (4.00–8.25)	0.3600
Facial pain, median (IQR)	1.00 (0.20–5.00)	1.60 (0.35–4.10)	0.8385
Headache, median (IQR)	2.25 (1.00–5.38)	2.70 (0.50–5.53)	0.9120
Sense of smell, median (IQR)	9.00 (7.25–9.73)	9.20 (5.18–10.00)	0.7381
Overall symptoms, median (IQR)	7.75 (5.38–9.00)	6.85 (4.00–7.15)	0.0519
36-item short-form health survey (SF-36)
Physical functioning, median (IQR)	80.00 (50.00–96.25)	92.50 (75.00–95.00)	0.2390
Role-physical, median (IQR)	62.50 (0.00–100.00)	75.00 (21.25–100.00)	0.4362
Bodily pain, median (IQR)	74.00 (52.00–100.00)	82.00 (74.00–100.00)0.0	0.0771
General health, median (IQR)	52.50 (30.00–77.75)	47.50 (35.00–67.00)	0.7754
Vitality, median (IQR)	67.50 (50.00–76.25)	62.50 (50.00–70.00)	0.4848
Social functioning, median (IQR)	75.00 (47.00–91.00)	81.25 (71.88–88.00)	0.6758
Role-emotional, median (IQR)	67.00 (0.00–100.00)	100.00 (24.75–100.00)	0.2290
Mental health, median (IQR)	68.00 (56.00–86.00)	64.00 (52.00–77.00)	0.4656

∗, P < 0.05. IQR, interquartile range.